August 17, 2017 Ball-and-stick model of the L-ascorbic acid (vitamin C) molecule, C6H8O6, as found in the crystal structure. Credit: public domain
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published online August 17 in the journal Cell.
Certain genetic changes are known to reduce the ability of an enzyme called TET2 to encourage stem cells to become mature blood cells, which eventually die, in many patients with certain kinds of leukemia, say the authors. The new study found that vitamin C activated TET2 function in mice engineered to be deficient in the enzyme.
"We're excited by the prospect that high-dose vitamin C might become a safe treatment for blood diseases caused by TET2-deficient leukemia stem cells, most likely in combination with other targeted therapies," says corresponding study author Benjamin G. Neel, MD, PhD, professor in the Department of Medicine and director of the Perlmutter Cancer Center.
Changes in the genetic code (mutations) that reduce TET2 function are found in 10 percent of patients with acute myeloid leukemia (AML), 30 percent of those with a form of pre-leukemia called myelodysplastic syndrome, and in nearly 50 percent of patients with chronic myelomonocytic leukemia. Such cancers cause anemia, infection risk, and bleeding as abnormal stem cells multiply in the bone marrow until they interfere with blood cell production, with the number of cases increasing as the population ages.
Along with these diseases, new tests suggest that about 2.5 percent of all U.S. cancer patients - or about 42,500 new patients each year - may develop TET2 mutations, including some with lymphomas and solid tumors, say the authors.
Cell Death Switch
The study results revolve around the relationship between TET2 and cytosine, one of the four nucleic acid "letters" that comprise the DNA code in genes. Every cell type has the same genes, but each gets different instructions to turn on only those needed in a given cellular context.
These "epigenetic" regulatory mechanisms include DNA methylation, the attachment of a small molecule termed a methyl group to cytosine bases that shuts down the action of a gene containing them.
The video will load shortly.
The back- and-forth attachment and removal of methyl groups also fine-tunes gene expression in stem cells, which can mature, specialize and multiply to become muscle, bone, nerve, or other cell types. This happens as the body first forms, but the bone marrow also keeps pools of stem cells on hand into adulthood, ready to become replacement cells as needed. In leukemia, signals that normally tell a blood stem cell to mature malfunction, leaving it to endlessly multiply and "self-renew" instead of producing normal white blood cells needed to fight infection.
The enzyme studied in this report, Tet methylcytosine dioxygenase 2 (TET2), enables a change in the molecular structure (oxidation) of methyl groups that is needed for them to be removed from cytosines. This "demethylation" turns on genes that direct stem cells to mature, and to start a count-down toward self-destruction as part of normal turnover. This serves as an anti-cancer safety mechanism, one that is disrupted in blood cancer patients with TET2 mutations, says Neel.
To determine the effect of mutations that reduce TET2 function in abnormal stem cells, the research team genetically engineered mice such that the scientists could switch the TET2 gene on or off.
Similar to the naturally occurring effects of TET2 mutations in mice or humans, using molecular biology techniques to turn off TET2 in mice caused abnormal stem cell behavior. Remarkably, these changes were reversed when TET2 expression was restored by a genetic trick. Previous work had shown that vitamin C could stimulate the activity of TET2 and its relatives TET1 and TET3. Because only one of the two copies of the TET2 gene in each stem cell is usually affected in TET2-mutant blood diseases, the authors hypothesized that high doses of vitamin C, which can only be given intravenously, might reverse the effects of TET2 deficiency by turning up the action of the remaining functional gene.
Indeed, they found that vitamin C did the same thing as restoring TET2 function genetically. By promoting DNA demethylation, high-dose vitamin C treatment induced stem cells to mature, and also suppressed the growth of leukemia cancer stem cells from human patients implanted in mice.
"Interestingly, we also found that vitamin C treatment had an effect on leukemic stem cells that resembled damage to their DNA," says first study author Luisa Cimmino, PhD, an assistant professor in the Department of Pathology at NYU Langone Health. "For this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause cancer cell death by blocking the repair of DNA damage, and already approved for treating certain patients with ovarian cancer."
Researchers found that the combination had an enhanced effect on leukemia stem cells, further shifting them from self-renewal back toward maturity and cell death. The results also suggest that vitamin C might drive leukemic stem cells without TET2 mutations toward death, says Cimmino, given that it turns up any TET2 activity normally in place.
"Our team is working to systematically identify genetic changes that contribute to risk for leukemia in significant groups of patients," says corresponding author Iannis Aifantis, PhD, professor and chair of the Department of Pathology at NYU Langone Health. "This study adds the targeting of abnormal TET2-driven DNA demethylation to our list of potential new treatment approaches."
Explore further: A tumor-suppressing gene can be harmful in some cancers
Journal reference: Cell
Provided by: NYU Langone Health / NYU School of Medicine
Adjust slider to filter visible comments by rank
Display comments: newest first
Very interesting. And what about the way in which Dr. Linus Pauling was ostracized by the scientific community as a quack for investing his career into this idea? Where is the deeper discussion of the effects that this has had upon this research? Why would the journalist fail to mention that it appears that the scientific community may have made a huge mistake?
' If you want a quote from his original paper that shows this better than anything, here it is: "We believe that the ascorbate-treated patients represent a random selection of all the terminal patients in the hospital, even though no formal randomization process was used." Suffice it to say that, in a clinical trial, it is not sufficient to "believe" that your groups were properly randomized and matched. You have to show it.'
Subsequent randomized clinical studies showed no benefit from high oral dosage of vitamin C in cancer. ' followed by two other randomized clinical trials, which when coupled with the first trial, involved 367 patients and failed to find a benefit from high-dose oral vitamin C in cancer. '
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Go here to see the original:
Vitamin C may encourage blood cancer stem cells to die - Medical Xpress
- In situ repair abilities of human umbilical cordderived mesenchymal stem cells and autocrosslinked hyaluronic acid gel complex in rhesus monkeys with... - May 23rd, 2020
- UH studying use of convalescent plasma to improve health of COVID-19 patients - Crain's Cleveland Business - May 23rd, 2020
- COVID-19: Recommendations for Treating MS and Related... : Neurology Today - LWW Journals - May 21st, 2020
- New hybrid embryos are the most thorough mixing of humans and mice yet - Science News - May 20th, 2020
- Hotel in Spain requires two negative Covid-19 tests to check in with a free antibody test during your stay - CNBC - May 20th, 2020
- 'Outpatient Is Still Chaos': What We Heard This Week - MedPage Today - May 20th, 2020
- Sumit Dewanjee, MD, is being recognized by Continental Who's Who - PRNewswire - May 7th, 2020
- Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine - BioSpace - May 7th, 2020
- COVID-19 Impact and Recovery Analysis | Global Cell Isolation Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and Becton,... - May 7th, 2020
- Stem Cell Alopecia Treatment Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026 - 3rd Watch News - May 7th, 2020
- AMC to use stem cell therapy in treating graft-versus-host disease - Korea Biomedical Review - May 7th, 2020
- Drumming class finds a new rhythm with creative connections - Yes! Weekly - May 7th, 2020
- Drumming class finds a new rhythm with creative connections - Wake Forest University News Center - May 5th, 2020
- Insights on the Worldwide Cell Expansion Industry to 2027 - Analysis and Forecasts - Yahoo Finance UK - May 5th, 2020
- These 5 Houston-area research institutions have bright minds at work to battle COVID-19 - InnovationMap - May 5th, 2020
- GCC Condemns Israeli Plans to Annex Parts of the West Bank - Asharq Al-awsat English - May 2nd, 2020
- Jerusalem residents concerned Israel is changing their residency rights - Arabnews - May 2nd, 2020
- Four UTSW Researchers Named to The National Academy of Sciences - D Magazine - May 1st, 2020
- CHMP Grants Positive Opinion for DARZALEX (daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma - Yahoo Finance - May 1st, 2020
- Verify the URL - InnovationMap - May 1st, 2020
- Houston banking exec shares tips for keeping online information secure amid COVID-19 threats - InnovationMap - May 1st, 2020
- Trials and Tribulations: Neurology Research During COVID-19 - Medscape - April 30th, 2020
- Into the Lungs and Beyond - Harvard Medical School - April 30th, 2020
- Five UC San Diego Professors Elected to National Academy of Sciences - UC San Diego Health - April 29th, 2020
- Suffering from ED? Discover how our combined treatments of Hormone Balancing and FDA Approved Acoustic Wave Pulse Therapy Ends Your ED - Magazine of... - April 29th, 2020
- BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT - BioSpace - April 29th, 2020
- What Is The Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting? - AJMC.com Managed Markets Network - April 24th, 2020
- Healing the heart by returning it to its infancy - FierceBiotech - April 24th, 2020
- What Factors Influence Hematological Recovery in Patients Who Receive CAR-T Therapies? - Cancer Therapy Advisor - April 24th, 2020
- Academy adds new members from UW who 'expand the boundaries of knowledge' - University of Wisconsin-Madison - April 24th, 2020
- FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments - FDA.gov - April 24th, 2020
- A rampage through the body - Science Magazine - April 24th, 2020
- Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post - April 21st, 2020
- Stem Cell Therapy: A Promising Treatment for COVID-19? - Technology Networks - April 21st, 2020
- Meet the 5 female finalists for the 2020 M&T Bank John Travers Award - PennLive - April 21st, 2020
- Hackensack Meridian Health Studying the Blood of COVID-19 Survivors - The Ritz Herald - April 15th, 2020
- Reviewing the Latest Treatment Strategies in Patients with Transplant-Eligible Multiple Myeloma - Hematology Advisor - April 9th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2026 | Takeda Pharmaceutical Company Limited, Cytori... - April 9th, 2020
- Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development - Business Wire - April 9th, 2020
- 3 drug candidates authorized to treat COVID-19 patients - Korea Biomedical Review - April 7th, 2020
- Surgeon offers innovative treatments - Brunswick News - April 7th, 2020
- Health Tech: Dallas-based American Heart Association Awards $14M in Research Grants for Heart, Brain, and COVID-19 Innovation - dallasinnovates.com - April 7th, 2020
- Metrion Biosciences and International Scientific Consortium Publish Data and New Recommendations for in Vitro Risk Assessment of the Cardiac Safety of... - April 7th, 2020
- YOUR HEALTH: Something fishy to help improve eyesight - WQAD.com - April 6th, 2020
- First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency... - April 6th, 2020
- Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular... - April 6th, 2020
- Coronavirus Business Tracker: How The Private Sector Is Fighting The COVID-19 Pandemic - Forbes - April 6th, 2020
- Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients - Associated Press - April 6th, 2020
- Coronavirus daily news update, April 6: What to know today about COVID-19 in the Seattle area, Washington state and the nation - Seattle Times - April 6th, 2020
- Celularity and Infectious Disease Research Institute will try out COVID-19 cell therapy - GeekWire - April 3rd, 2020
- Pinprick Blood Test To Identify Antibodies In Patients Approved By FDA - Kaiser Health News - April 3rd, 2020
- CytoDyn CEO Dr. Pourhassan to Appear on Fox Business Network Friday, April 3, 2020 at 2:00 pm ET to Discuss Leronlimab Treatment of 10 Severely Ill... - April 3rd, 2020
- Is There a New CAR T-Cell Treatment for Mantle Cell Lymphoma? - AJMC.com Managed Markets Network - April 3rd, 2020
- North Jersey hitting the surge - Politico - April 3rd, 2020
- PharmAbcine Announces Acceptance of Phase Ib Olinvacimab and Pembrolizuamb Combination Trial in rGBM Patients Abstract at the 2020 ASCO Annual Meeting... - April 3rd, 2020
- A word for those risking their lives amid the coronavirus crisis: Thanks - TwinCities.com-Pioneer Press - April 3rd, 2020
- AML Relapse: How IDH-Inhibitor Drugs Work To Achieve Remission Before Stem-Cell Transplant - SurvivorNet - April 2nd, 2020
- Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients - Associated Press - March 31st, 2020
- 2020 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research That Impact Human Health - Benzinga - March 31st, 2020
- Sales Revenue of Scaffold Technology Market to Escalate in the Coming Years Owing to Rapid Growth in Consumer Adoption 2017 2025 - Lake Shore Gazette - March 31st, 2020
- San Diego Angel Conference Announces Investment of $400,000 in 3 Companies - Times of San Diego - March 31st, 2020
- About Stem Cell Center - March 28th, 2020
- From Bats to Human Lungs, the Evolution of a Coronavirus - The New Yorker - March 28th, 2020
- Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with... - March 28th, 2020
- Live Updates: Coronavirus in the Bay Area: Phony Health 'Inspectors' Knocking on Doors -- Don't Let Them In - KQED - March 28th, 2020
- Veterans in Pain helps ease the pain for veterans - Tullahoma News and Guardian - March 25th, 2020
- Disruptions in Cancer Care in the Era of COVID-19 - Medscape - March 21st, 2020
- In vivo Comparison of the Biodistribution and Toxicity of InP/ZnS Quan | IJN - Dove Medical Press - March 21st, 2020
- A new therapeutic approach against COVID-19 Pneumonia - Institute for Ethics and Emerging Technologies - March 15th, 2020
- Toxicity minimal with novel transplantation approach for transfusion-dependent thalassemia - Healio - March 12th, 2020
- OncMadness: Meet the Blue Ribbon Panel - MedPage Today - March 12th, 2020
- Hatteras Island Cancer Foundation Celebrates 20 Years with Upcoming Annual Gala - Island Free Press - March 12th, 2020
- Scientists Grapple with US Restrictions on Fetal Tissue Research - The Scientist - March 2nd, 2020
- CAR T Cells to Go? Outpatient Therapy Can Be Safe - Medscape - February 28th, 2020
- TO YOUR HEALTH: Inflammation can drive triple-negative breast cancer - Dover Post - February 28th, 2020
- Impact of TP53 Mutation Clearance Prior to Allo-SCT - MedPage Today - February 28th, 2020
- Arctic Medical Center: Regenerative Medicine & Stem Cell ... - February 27th, 2020
- New study identifies trigger that turns dormant cancer stem cells into active ones - Benzinga - February 27th, 2020
- Bringing Transplant to More Patients With AML - MedPage Today - February 27th, 2020
- UCLA raises $5.49 billion in one of most ambitious campaigns ever by a public university - UCLA Newsroom - February 27th, 2020